by Communication Team | Jan 21, 2021 | ODYSSEY, Publication
On 12 January 2021, the European Medicine Agency approved the use of dolutegravir 5mg dispersible tablets for treating HIV in young children living in Europe. This decision was based, in part, on data from our ODYSSEY trial, which we are conducting in close...
by Communication Team | Dec 21, 2020 | ODYSSEY
With the world engulfed by the COVID-19 pandemic, you may not have heard about some of the breakthroughs that the scientific community has made in the treatment of paediatric HIV. One such breakthrough is the development of dispersible dolutegravir. Find more on...
by Communication Team | Nov 19, 2020 | ODYSSEY
On November 12th, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending marketing authorisation for dolutegravir 5mg dispersible tablets for young children living with HIV. This decision...
by Communication Team | Aug 6, 2020 | ODYSSEY
Results from a sub-study of the ODYSSEY trial, published in The Lancet HIV journal, show that children over 20kg in weight can safely take adult doses (50mg) of the anti-HIV drug dolutegravir. With over half of children living with HIV globally weighing at over 20kg,...
by Communication Team | Jun 29, 2020 | ODYSSEY
Picturing Health have developed a short video explaining how dolutegravir (DTG), using preliminary data from the ODYSSEY trial, has gained approval for use in children. Picturing Health is a non-profit film producer with the aim to improve public health. Click here to...
by Communication Team | Jun 29, 2020 | ODYSSEY
Data from the ongoing P1093 and ODYSSEY (PENTA20) studies have led to the successful approval of ViiV Healthcare’s submission to the U.S. Food and Drug Administration (FDA) of the adult formulation for children weighing ≥20kg and dolutegravir (DTG) dispersible tablets...
Recent Comments